Skip to main content

Advertisement

Log in

Blood transfusion in marrow graft recipients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Of 182 consecutive patients undergoing allogeneic bone marrow transplantation (BMT), the relative numbers of those who received red blood cells (RBC), platelets (PLT), and granulocytes were 82%, 96%, and 26%, respectively. The transfused patients received an average of 1.26 (SD±2.0) RBC units, 9.41 (SD±13.2) PLT transfusions, and 0.33 (SD±1.1) granulocyte concentrates per week per 50 kg body wt. in the period starting on the day of bone marrow transplantation (BMT) up to 60 days post BMT. The total number of units per transfused patient was 7.7 (range 1–63) RBC, 55.2 (range 2–394) PLT and 6.2 (range 1–36) granulocytes in the same period. Patients with grades II-IV acute graftversus-host disease (GVHD) needed more RBC and PLT (p < 0.001) than patients with grades 0-I acute GVHD. Patients with late engraftment required more granulocyte and PLT transfusion than those with early engraftment (p < 0.05). Patients with high-risk malignancy had greater need for RBC and PLT than “low-risk patients” (p<0.02 andp<0.01), respectively). Patients with major ABO-incompatible donors showed a greater need for RBC than patients with minor ABO incompatibility (p=0.02) or ABO identical donors (p=0.01). Patients with relatively poor estimated survival required the most RBC and PLT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bacigalupo A, Van Lint M, Occhini D, Margiocco M, Ferrari G, Pittaluga P, Frassoni F, Peralvo J, Lercari G, Carubia F, Marmont A (1988) ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 45: 1091–1094

    PubMed  Google Scholar 

  2. Bensinger WI, Buckner CD, Thomas ED, Clift RA (1982) ABO-incompatible marrow transplants. Transplantation 33: 427–429

    PubMed  Google Scholar 

  3. Bensinger W, Petersen F, Banai M, Buchner D, Clift R, Slichter S, Storb R, Ihowas D (1989) Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission. Bone Marrow Transplant 4: 401–414

    Google Scholar 

  4. Blacklock A, Katy F, Michalewicz R (1984) A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation. Br J Hematol 58: 267–276

    Google Scholar 

  5. Braine H-G, Sensenbrenner LL, Wright SK, Tutschka PJ, Saral R, Santos G (1979) Erythrocyte-incompatible bone marrow transplant. In: Baum SJ, Ledney GD (eds) Experimental hematology today. Springer, Berlin Heidelberg New York, pp 215–217

    Google Scholar 

  6. Brand A, Claas FMJ, Falkenberg JHF (1984) Blood component therapy in bone marrow transplantation. Semin Hematol 21: 141–155

    PubMed  Google Scholar 

  7. Breslow NE, Day NE, Davis W (1988) In: Davis W (ed) Statistical methods in cancer research, vol 1. The analysis of case-control studies. International Agency for Research on Cancer, Lyon

    Google Scholar 

  8. Gale RP, Feig S, Ho W, Falk P, Rippee C, Sparkes R, for the UCLA Marrow Transplant Team (1977) ABO blood group systems and bone marrow transplantation. Blood 50: 185–190

    PubMed  Google Scholar 

  9. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A (1991) Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338: 1223–1226

    PubMed  Google Scholar 

  10. öst L, Lönnqvist B, Eriksson L, Ljungman P, Ringden O (1987) Hemorrhagic cystitis — a manifestation of graft-versus-host disease? Bone Marrow Transplant 2: 19–25

    PubMed  Google Scholar 

  11. Osterwalder B, Gratwohl A, Reusser P, Tichelli A, Speck B (1988) Hematological support in patients undergoing allogeneic bone marrow transplantation. Recent Results Cancer Res 108: 44–52

    PubMed  Google Scholar 

  12. Paulin T, Ringdén O, Nilsson B, Lönnqvist B, Gahrton G (1987) Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation 43: 393–398

    PubMed  Google Scholar 

  13. Ringdén O, Lönnqvist B, Lundgren G, Gahrton G, Groth CG, Möller E, Báryd I, Johansson B, Pihlstedt P, Gullbring B (1982) Experience with a cooperative bone marrow transplantation program in Stockholm. Transplantation 33: 500–504

    PubMed  Google Scholar 

  14. Ringdén O, BÄckman L, Lönnqvist B, Heimdahl A, Lindholm A, Bolme P, Gahrton G (1986) A randomized trial comparing the use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancies. Bone Marrow Transplant 1: 41–51

    PubMed  Google Scholar 

  15. Ringdén O, Pihlstedt P, Markling L, Aschan J, Báryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B (1991) Prevention of graft-versus-host disease with T-cell depletion or cyclosporine combined with methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 7: 221–226

    PubMed  Google Scholar 

  16. Sniecinski I, Henry S, Ritchey B, Branch D, Blume K (1985) Erythrocyte depletion of ABO-incompatible bone marrow. J Clin Apheresis 2: 231–234

    PubMed  Google Scholar 

  17. Sniecinski I, Oien L, Petz L, Blume K (1988) Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 45: 530–534

    PubMed  Google Scholar 

  18. Storb R, Weiden P (1981) Transfusion problems associated with transplantation. Semin Hematol 18: 163–176

    PubMed  Google Scholar 

  19. Storb R, Deeg HJ, Whitehead J, Farewell V, Appelbaum RF, Beatty P, Bensinger W, Buckner CD, Clift RA, Doney K, Hansen JA, Hill R, Lum LG, Martin P, McGuffin R, Sanders JE, Singer J, Stewart P, Sullivan KM, Witherspoon RP, Thomas ED (1987) Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 19: 2608–2613

    PubMed  Google Scholar 

  20. Thomas ED (1983) Marrow transplant for acute nonlymphoblastic leukemia in first remission in a follow-up. N Engl J Med 308: 1539–1540

    PubMed  Google Scholar 

  21. Warkentin PI (1983) Transfusion of patients undergoing bone marrow transplantation. Hum Pathol 14: 261–266

    PubMed  Google Scholar 

  22. Weiden P, Slichter S & Banaji M (1978) Marrow transplantation for aplastic anemia and leukemia. In: The blood platelet in transfusion therapy. Alan R Liss, New York, pp 295–312

    Google Scholar 

  23. Widmann (1984) Technical manual AABB, 8th edn. Lippincott, Philadelphia

    Google Scholar 

  24. Wulff J, Santner T, Storb R, Banaji M, Buckner D, Clift R, Stewart P, Sanders J, Slichter S, Thomas ED (1983) Transfusion requirements after HLA-identical marrow transplantation in 82 patients with aplastic anemia. Vox Sang 44: 366–375

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pihlstedt, P., Paulin, T., Sundberg, B. et al. Blood transfusion in marrow graft recipients. Ann Hematol 65, 66–70 (1992). https://doi.org/10.1007/BF01698131

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01698131

Key words

Navigation